ImaginAb reported trial results in the Journal of Nuclear Medicine showing that patients with solid malignancies were able to tolerate its CD8 zirconium-89 IAB22M2C T-cell PET imaging agent without side effects. The agent, which successfully targeted CD8-positive T-cell-rich tissues, may be beneficial in evaluating within-tumor buildup of CD8-positive T-cells, according to ImaginAb.
ImaginAb reports efficacy of T-cell PET agent in solid tumors
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.